PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

February 19, 2021

Study Completion Date

May 15, 2021

Conditions
Squamous Cell CarcinomaOropharynx Cancer
Interventions
RADIATION

Intensity modulated radiotherapy (IMRT)

Intensity modulated radiotherapy (IMRT) will be delivered over 6.5 weeks in 33 daily fractions. Treatments will be initiated on Monday or Tuesday. Missed treatments will be compensated for by delivering an additional BID treatment during the week given at least 6 hours apart OR treating on the Saturday of that week, OR adding to the end of treatment. Gross disease will receive 70 Gy in 2.12 Gy fractions, areas at high-risk for subclinical disease will receive 60 Gy in 1.82 Gy fractions, and areas at low-risk for harboring subclinical disease will receive 56 Gy in 1.70 Gy fractions.

DIAGNOSTIC_TEST

PET-MRI

All imaging data will be acquired using a 3.0T PET-MRI scanner with a standard bore size of 60 cm. Patients will be placed in standard non-ferrous head and neck immobilization devices during PET-MRI to simulate their anticipated positioning during subsequent CT simulation and treatment. A head and neck PET-MRI study will be performed with scan sequences tailored for the site of interest. The PET-MRI exam will take approximately 90 minutes to complete.

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT03342378 - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients | Biotech Hunter | Biotech Hunter